Bone Biologics (BBLG) risk factors

72 risks, 1 new, 15 reworded since the prior year. Bone Biologics restructured its entire risk section, completely swapping the content of multiple risk categories between headers. Federal net operating loss carryforwards increased from $34,585,000 as of December 31, 2024 to $46,140,000 as of December 31, 2025. A new risk was added concerning potential expenses, litigation, and trade secret exposure related to intellectual property.

71 risks. Bone Biologics faces severe going concern doubts, relying on $4.1M cash to fund operations through late 2025.